I am a
Home I AM A Search Login

Papers of the Week

2021 Jun 29


Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.


Østergaard L, Vesikari T, Senders SD, Flodmark C-E, Kosina P, Jiang H-Q, Maguire JD, Absalon J, Jansen KU, Harris SL, Maansson R, Balmer P, Beeslaar J, Perez JL
Vaccine. 2021 Jun 29.
PMID: 34215452.


To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents.